Research programme: calpain inhibitors - Contineum Therapeutics
Latest Information Update: 30 Jun 2025
At a glance
- Originator Contineum Therapeutics
- Class Small molecules
- Mechanism of Action Calpain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 30 Jun 2025 Preclinical trials in Unspecified in USA (unspecified route) (Continuem Therapeutics pipeline, July 2025)